Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1677 1678
This examiner grants 61% of resolved cases
Christopher Ryan Evans, an examiner in Tech Center 1600 and Art Unit 1677, has 23 resolved cases. The allowance rate is 60.9 percent, indicating a moderate success rate for applicants. However, the median days to allowance is 1413, which is a very long period for prosecution that requires a significant time investment from the applicant.
The most significant metric is the interview lift of 64.3 percent. This suggests that conducting an interview more than doubles the likelihood of allowance compared to the 60.9 percent baseline. For the 23 resolved cases, the 64.3 percent lift is a strong signal that verbal advocacy is highly effective, even with the 1413-day wait for a grant. Practitioners should prioritize interviews to take advantage of this 64.3 percent increase in the probability of success. The combination of a 60.9 percent allowance rate and a 64.3 percent lift makes interviews a critical component of any strategy with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18045845 | METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-B-CORONAVIRUS ANTIBODY IN A SAMPLE | Non-Final OA | Abbott Laboratories |
| 17503122 | ANTIBODY POTENCY ASSAY | Final Rejection | Genentech, Inc. |
| 18365476 | TETHERED DETECTION ASSAYS | Non-Final OA | Singular Genomics Systems, Inc. |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18677132 | ANALYSIS METHOD | Non-Final OA | DENSO CORPORATION |
| 17495133 | METHOD OF AMPLIFYING FLUORESCENT SIGNAL THROUGH CYCLIC STAINING OF TARGET MOLECULES VIA FLUOROPHORE-CONJUGATED COMPLEMENTARY ANTIBODIES | Final Rejection | Korea Advanced Institute Of Science And Technology |
| 17677255 | STRUCTURE AND METHODS FOR DETECTION OF SAMPLE ANALYTES | Final Rejection | Nautilus Subsidiary, Inc. |
| 18698098 | FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT | Non-Final OA | AMGEN INC. |
| 17705924 | Methods for Detecting Symmetrical Dimethylarginine | Non-Final OA | IDEXX Laboratories, Inc. |
| 17793171 | ACTIVITY-SPECIFIC CELL ENRICHMENT | Non-Final OA | ABSCI Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy